Odanacatib Phase III Success Suggests Merck’s Primary Care Gamble Is Paying Off
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A data monitoring committee’s early termination of a 16,000-patient Phase III study of Merck’s cap-K inhibitor odanacatib suggests the osteoporosis therapy could have a competitive profile. The drug will need to offer significant advantages to cut it in the crowded market already saturated with generics.